Circulating Biomarkers for Cardiovascular Diseases
Cardiovascular diseases (CVD) remain the No. 1 killer in industrial countries and a main reason for frequent re-hospitalization. Biomarker testing may play a central role in promoting improved clinical outcome, better quality of life, and alleviated socio-economic burden of CVD. Even in this post-cTn (cardiac troponin) and post-BNP (B-type natriuretic peptide) era, there are still significant gaps and demands for more reliable and innovative biomarker-based tools for diagnosis and evidence-guided management of CVD. This Special Issue of Acta Pharmacologica Sinica consists of 18 original research or review articles authored by 108 scientists from 15 countries to showcase recent advances in translational and clinical investigations focusing on biomarkers that are released from injured cardiovascular tissues into circulation during various CVD events, such as acute myocardial infarction, heart failure, aortic aneurysms, carotid restenosis, pulmonary hypertension, and cardiac amyloidosis. These collective efforts can benefit future technological development of novel tests for CVD biomarkers.
1. Lei XI (Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298-0204, USA);
2. George KOUVELOS (Department of Vascular Surgery, University of Thessaly, Larissa, Greece);
3. Nazareno PAOLOCCI (Heart & Vascular Institute, Johns Hopkins University, Baltimore, MD 21205, USA)
